| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1106826673 |
| P356 | DOI | 10.1186/S12967-018-1624-2 |
| P932 | PMC publication ID | 6127986 |
| P698 | PubMed publication ID | 30189880 |
| P50 | author | Diego de Miguel-Pérez | Q87364644 |
| Carmen Garrido-Navas | Q91097901 | ||
| P2093 | author name string | Jose A Lorente | |
| Hugh Ilyine | |||
| Francisco G Ortega | |||
| Jose L García-Puche | |||
| Alba Rodriguez-Martínez | |||
| Jose Exposito-Hernandez | |||
| M José Serrano | |||
| Mayte Delgado-Ureña | |||
| Miguel Delgado-Ramirez | |||
| P2860 | cites work | Simulation study of confounder-selection strategies. | Q52884423 |
| Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status | Q81520460 | ||
| Dynamic changes in numbers and properties of circulating tumor cells and their potential applications | Q26853569 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| VEGF targets the tumour cell | Q33573324 | ||
| The VEGF family in cancer and antibody-based strategies for their inhibition | Q33733437 | ||
| A systematic review of treatment guidelines for metastatic colorectal cancer | Q33995028 | ||
| Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer | Q34328567 | ||
| EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer | Q34365738 | ||
| Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials | Q34654605 | ||
| Rapid vascular regrowth in tumors after reversal of VEGF inhibition | Q35052385 | ||
| VEGF expression by epithelial and stromal cell compartments: resolving a controversy | Q35745892 | ||
| Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST | Q36015295 | ||
| Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer | Q36213034 | ||
| Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutat | Q36213108 | ||
| Biomarkers characterization of circulating tumour cells in breast cancer patients | Q36245346 | ||
| Primary Tumor Resection Is Associated with Improved Survival in Stage IV Colorectal Cancer: An Instrumental Variable Analysis | Q36275579 | ||
| Vascular endothelial growth factor signaling pathways: therapeutic perspective | Q36584934 | ||
| Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients | Q36796137 | ||
| Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer | Q37083038 | ||
| Significance of different response evaluation criteria in predicting progression-free survival of lung cancer with certain imaging characteristics | Q37458481 | ||
| Metastatic colorectal cancer-prolonging overall survival with targeted therapies | Q37481713 | ||
| Circulating Tumor Cells and Colorectal Cancer. | Q37796603 | ||
| Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies | Q38097525 | ||
| Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance | Q38351432 | ||
| The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression | Q42441491 | ||
| Predictive biomarkers for bevacizumab: are we there yet? | Q45738579 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 251 | |
| P577 | publication date | 2018-09-06 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients | |
| P478 | volume | 16 |
Search more.